MYD88L265P augments proximal B-cell receptor signaling in large B-cell lymphomas via an interaction with DOCK8
Blood · 2023
DOI: 10.1182/blood.2023019865 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, 2023. Verfasst von Elisa Mandato und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Myeloid Differentiation Factor 88. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 57 Literaturangaben.
Abstract (Originalsprache)
Diffuse large B-cell lymphoma (DLBCL) is a clinically and genetically heterogeneous disease with at least 5 recognized molecular subtypes. Cluster 5 (C5)/MCD tumors frequently exhibit concurrent alterations in the toll-like receptor (TLR) and B-cell receptor (BCR) pathway members, MYD88L265P and CD79B, and have a less favorable prognosis. In healthy B cells, the synergy between TLR and BCR signaling pathways integrates innate and adaptive immune responses and augments downstream NF-κB activation. In addition, physiologic TLR9 pathway engagement via MYD88, protein tyrosine kinase 2 (PYK2), and dedicator of cytokinesis 8 (DOCK8) increases proximal BCR signaling in healthy murine B cells. Although C5/MCD DLBCLs are selectively sensitive to Bruton tyrosine kinase (BTK) inhibition in in vitro studies and certain clinical trials, the role of mutated MYD88 in proximal BCR signaling remains undefined. Using engineered DLBCL cell line models, we found that concurrent MYD88L265P and CD79B alterations significantly increased the magnitude and duration of proximal BCR signaling, at the level of spleen tyrosine kinase and BTK, and augmented PYK2-dependent DOCK8 phosphorylation. MYD88L265P DLBCLs have significantly increased colocalization of DOCK8 with both MYD88 and the proximal BCR-associated Src kinase, LYN, in comparison with MYD88WT DLBCLs, implicating DOCK8 in MYD88L265P/proximal BCR cross talk. Additionally, DOCK8 depletion selectively decreased proximal BCR signaling, cellular proliferation, and viability of DLBCLs with endogenous MYD88L265P/CD79BY196F alterations and increased the efficacy of BTK blockade in these lymphomas. Therefore, MYD88L265P/DOCK8-enhanced proximal BCR signaling is a likely mechanism for the increased sensitivity of C5/MCD DLBCLs to BTK blockade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
- Bristol Myers Squibb, Cambridge, MA.
- Parthenon Therapeutics, Boston, MA.
- Department of Pathology, University of Rochester Medical Center, Rochester, NY.
- Max Planck Institute for Biology of Ageing, Cologne, Germany.
- Department of Hematology, Oncology, and Tumor Immunology, Charité - University Medical Center Berlin, Campus Benjamin Franklin, Berlin, Germany.
ORCID-Profile: Elisa Mandato, Qingsheng Yan, Julia Paczkowska, Yansheng Hao, Kamil Bojarczuk, Julia Hansen, Björn Chapuy, Scott J Rodig, Sumbul Jawed Khan, Robert A Redd, Margaret A Shipp
Zitieren
APA
Mandato, E., Yan, Q., Ouyang, J., Paczkowska, J., Qin, Y., Hao, Y., Bojarczuk, K., Hansen, J., Chapuy, B., Rodig, S. J., Khan, S. J., Redd, R. A., & Shipp, M. A. (2023). MYD88L265P augments proximal B-cell receptor signaling in large B-cell lymphomas via an interaction with DOCK8. Blood. https://doi.org/10.1182/blood.2023019865
Vancouver
Mandato E, Yan Q, Ouyang J, Paczkowska J, Qin Y, Hao Y, et al. MYD88L265P augments proximal B-cell receptor signaling in large B-cell lymphomas via an interaction with DOCK8. Blood. 2023. doi:10.1182/blood.2023019865
BibTeX
@article{Mandato2023,
author = {Mandato, Elisa and Yan, Qingsheng and Ouyang, Jing and Paczkowska, Julia and Qin, Yan and Hao, Yansheng and Bojarczuk, Kamil and Hansen, Julia and Chapuy, Björn and Rodig, Scott J and Khan, Sumbul Jawed and Redd, Robert A and Shipp, Margaret A},
title = {MYD88L265P augments proximal B-cell receptor signaling in large B-cell lymphomas via an interaction with DOCK8},
journal = {Blood},
year = {2023},
doi = {10.1182/blood.2023019865}
}
EUVIMED